ModerateDirect oral anticoagulants (factor Xa inhibitors)×Reversible P2Y12 receptor inhibitor
Updated · Methodology
Mechanism
Apixaban directly and reversibly inhibits coagulation factor Xa. Ticagrelor reversibly blocks the platelet P2Y12 receptor and so prevents platelet activation and aggregation (apixaban and ticagrelor summaries of product characteristics, SmPCs, European Medicines Agency, EMA). The two drugs act on different parts of haemostasis, and the apixaban SmPC names P2Y12 inhibitors among the drugs that generally increase the risk of bleeding (EMA). Ticagrelor is a weak inhibitor of the CYP3A4 enzyme and of P-glycoprotein (P-gp), and no apixaban dose adjustment is needed with inhibitors that are not strong (ticagrelor and apixaban SmPCs, EMA).
Symptoms
The risk of overt or occult bleeding in any tissue or organ rises, and bleeding may lead to post-haemorrhagic anaemia. Signs and severity depend on the site and extent of bleeding (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Common adverse reactions with apixaban are haemorrhage, contusion, nosebleeds and haematoma (EMA). The most frequently reported adverse reactions with ticagrelor are bleeding and shortness of breath (ticagrelor SmPC, EMA). In a clinical study in adults with atrial fibrillation, adding acetylsalicylic acid to apixaban raised major bleeding from 1.8% to 3.4% a year (apixaban SmPC, EMA).
Management
There is no contraindication for this pair. Use apixaban with caution together with P2Y12 inhibitors. In atrial fibrillation that requires single or dual antiplatelet therapy, carefully weigh the potential benefits against the potential risks before combining the drugs (apixaban summary of product characteristics, SmPC, European Medicines Agency, EMA). After surgery, the SmPC does not recommend combining apixaban with other platelet aggregation inhibitors (EMA). If the combination is clinically indicated, use ticagrelor with caution in patients who take oral anticoagulants within 24 hours of a ticagrelor dose (ticagrelor SmPC, EMA). Give ticagrelor with a low maintenance dose of acetylsalicylic acid, 75–150 mg a day, unless it is contraindicated (EMA), and use acetylsalicylic acid with apixaban with caution, especially in older patients (apixaban SmPC, EMA). There are no data on this combination, and the European Heart Rhythm Association practical guide (EHRA 2021) calls for careful monitoring. The same guide notes that the 2020 European Society of Cardiology guidelines discourage ticagrelor as part of triple therapy, while dual therapy with ticagrelor could be considered after an acute coronary syndrome in patients at high thrombotic and low bleeding risk (EHRA 2021). Stop apixaban if severe bleeding occurs (apixaban SmPC, EMA). Before elective surgery, if an antiplatelet effect is not needed, stop ticagrelor 5 days in advance (ticagrelor SmPC, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Apixabán (nº registro 111691009), sección 4.4 (2026)– AEMPS, CIMA, nº registro 111691009, sección 4.4, texto de la EMA publicado en CIMA, consultado en septiembre de 2026
- AEMPS: Ficha técnica de Eliquis 5 mg comprimidos recubiertos con película (apixabán) (2026)– AEMPS, CIMA (texto EMA), nº registro 111691009, secciones 4.4 y 4.5
- FDA: Eliquis (apixaban) prescribing information (2025)– FDA, DailyMed, Eliquis, E.R. Squibb & Sons, setid e9481622-7cc6-418a-acb6-c5450daae9b0, revisión 04/2025, secciones 4 y 7.1
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- EMA: Ficha técnica: Ticagrelor (EU/1/10/655), secciones 4.4 y 4.5 (2026)– EMA, ficha técnica de Brilique (EU/1/10/655) en CIMA, nº registro 10655004, texto vigente en CIMA a 03/10/2026, sin fecha de revisión, secciones 4.4 y 4.5